SpectraCure AB (DE:2OK)
FRANKFURT:2OK
Want to see DE:2OK full AI Analyst Report?
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€3.90M
Enterprise Value€18.16M
Total Cash (Recent Filing)€13.53M
Total Debt (Recent Filing)€3.01M
Price to Earnings (P/E)―
Beta-84.76
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow absolute debt versus a substantial equity base reduces immediate solvency and interest burden risks, giving the company more flexibility to fund development through equity or grants. This conservative leverage profile is a durable buffer while commercialization is pursued.
Proprietary IDOSE PDT PlatformA focused, proprietary technology platform targeting interstitial photodynamic therapy creates a structural competitive advantage if clinically validated. The combination of fiber-optic delivery and real-time dosing addresses an unmet clinical need and can create barriers to entry and durable differentiation.
Lean Operating StructureA small, focused team implies lower fixed overhead and potentially more capital-efficient R&D execution in the near term. For an early-stage medtech developer, lean operations can extend runway and concentrate resources on clinical milestones that drive long-term value creation.
Bears Say
Accelerating Cash BurnPersistently negative and worsening free cash flow indicates the company is consuming substantial cash to progress development. Unless FCF turns toward break-even or financing is secured, reliance on external capital raises dilution and execution risk over the next several quarters.
Minimal Commercial RevenueThe firm remains effectively pre-commercial with negligible recurring revenue, meaning operating expenses are not being offset by product sales. This structural lack of revenue extends dependence on funding and makes long-term sustainability contingent on successful commercialization.
Widening Net Losses And Equity ErosionMaterial widening of net losses and a declining equity base reflect sustained cash burn and recurring funding events. This trend undermines balance sheet resilience over time and increases the likelihood of future dilution or financing at unfavorable terms if operational progress doesn't reduce losses.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €3.90M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 30 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.